NASDAQ:RACA

Therapeutics Acquisition (RACA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$7.67
$10.48
52-Week Range
N/A
Volume
N/A
Average Volume
105,531 shs
Market Capitalization
$175.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RACA stock logo

About Therapeutics Acquisition Stock (NASDAQ:RACA)

Therapeutics Acquisition Corp., doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts.

RACA Stock News Headlines

Halozyme Therapeutics
RACA/USD - RACA US Dollar
Karuna Therapeutics Inc KRTX
Amgen Concludes Horizon Therapeutics Acquisition
Novartis Completes Acquisition of Chinook Therapeutics
HDL Therapeutics to Go Public in SPAC Deal
See More Headlines
Receive RACA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Therapeutics Acquisition and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RACA
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$175.51 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Peter Kolchinsky Ph.D. (Age 44)
    Chairman & CEO
  • Dr. Matthew Hammond M.B.A. (Age 32)
    Ph.D., CFO, Chief Accounting Officer, Sec. & Director

This page (NASDAQ:RACA) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners